目的 构建以聚乙二醇单甲醚-聚乳酸共聚物(MPEG-PLGA)纳米粒为核心的三七总皂苷复合纳米囊泡(PNS-CNV),对该复合纳米囊泡的理化性质及对大鼠急性心肌缺血损伤的保护作用进行考察。方法 采用复乳-溶剂挥发法制备不同相对分子质量的聚乙二醇单甲醚-聚乳酸共聚物三七总皂苷纳米粒(PNS-NP),以三七总皂苷纳米粒为核心,采用薄膜分散法对其进行包封,制备三七总皂苷复合纳米囊泡;采用超滤法、透射电镜、纳米粒度仪,测定三七总皂苷复合纳米囊泡各指标成分的包封率及其理化性质;建立大鼠急性心肌缺血模型,考察三七总皂苷复合纳米囊泡对心肌及血清中生化指标的影响。结果 聚乙二醇单甲醚-聚乳酸共聚物的相对分子质量对三七总皂苷复合纳米囊泡的包封率、粒径及Zeta电位没有显著性影响。药效结果显示,与三七总皂苷水溶液组相比,三七总皂苷复合纳米囊泡组大鼠心肌组织中SOD活力显著提高、H2O2及丙二醛含量降低,血清中乳酸脱氢酶(LDH)活力降低(P<0.05),并且以相对分子质量5000的聚乙二醇单甲醚-聚乳酸共聚物为载体的三七总皂苷复合纳米囊泡的保护作用最优。结论 复合纳米囊泡作为三七总皂苷的口服给药传递系统,应用前景广泛。
Abstract
OBJECTIVE To prepare Panax notoginseng saponins-loaded complex nano vesicles (PNS-CNV) with MPEG-PLGA nanoparticles as the core and investigate the physicochemical property of PNS-CNV and protective action on acute myocardial ischemia in rats. METHODS Double emulsification-solvent evaporation method was used to prepare Panax notoginseng saponins-loaded nanoparticles using different molecular weight MPEG-PLGA (PNS-NP). Thin-film hydration method was applied to entrap PNS-NP as the core to form PNS-CNV. Ultrafiltration, transmission electron microscope, dynamic light scattering and electrophoretic light scattering were employed to study the entrapment efficiency of each index component in PNS and physicochemical parameters of PNS-CNV. Acute myocardial ischemia model in rats was established to investigate the protective effect of PNS-CNV. RESULTS The molecular weight of MPEG-PLGA did not affect the entrapment efficiency, particle size and Zeta potential of PNS-CNV. The pharmacodynamic experiment indicated that comparing with PNS solution group, the SOD activity of rat myocardium in PNS-CNV group was elevated with markedly decreased H2O2, MDA and serum LDH activity (P<0.05). The protective effect of PNS-CNV with MPEG5000-PLGA was the most significant. CONCLUSION CNV may be used as potential new oral drug delivery carriers.
关键词
聚乙二醇单甲醚-聚乳酸共聚物 /
复合纳米囊泡 /
理化性质 /
急性心肌缺血
{{custom_keyword}} /
Key words
MPEG-PLGA /
complex nano vesicle /
physicochemical property /
acute myocardial ischemia
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] XUN Q F. Studies on the High Bioavailability of Saponins of Panax Notoginseng . Shanghai:Doctorate Dissertation of Fudan University, 2003. [2] ZHOU Y, TIAN L, LI J Q, et al. The effect of Panax notoginseng saponins on myocardium hypertrophy induceded by norepinephrine . J Guangxi Med Univ(广西医科大学学报), 2005, 22 (6):910-912. [3] CHAN P, THANAS C N, TROMLINSON B. Protective effects of trilinolein extracted from Panax notoginseng against cardiovascular disease . Acta Pharmacol Sin(中国药理学报), 2002, 23 (12):1157-1162. [4] HAN M, HAN L M, WANG Q S, et al. Mechanism of oral absorption of Panax notoginseng saponins . Acta Pharm Sin (药学学报), 2006, 41 (6):498-505. [5] ZHOU Q, HE W, ZHOU L, et al. Protective effects of total saponins of Panax notoginseng on myocardial hypertrophy induced by isoproterenol in rats . Lishizhen Med Mater Med Res(时珍国医国药杂志), 2006, 17 (4):506-507. [6] WANG J, ZHANG Y F, SHAO Q, et al. Serum metabolome analysis reveals effect of Panax notoginosides on ischemic rat after acute myocardial infarction . China J Chin Mater Med(中国中药杂志), 2010, 35 (23):3199-3202. [7] ZOU L, LENG J, LIU Y, et al. Progress of new preparations of Panax notoginseng Saponins . Sichuan Trad Chin Med(四川中医), 2010, 28 (3):23-25. [8] WU J F, YU D H, FANG C, et al. Preparation and release study of methotrexate loaded PLGA-nanocapsules in vitro. Chin Pharm J(中国药学杂志), 2010, 45 (2):120. [9] CHEN T, HOU S X. Mitoxantrone hydrochloride liposome, the preparation and pharmaceutical properties . Chin Pharm J (中国药学杂志), 2005, 40 (7):522-525. ZHENG H S, ZUOLA S, WANG X L, et al. Determination of entrapment efficiency of sinomenine hydrochloride liposomes with centrifugation sedimentation combined with centrifugation ultrafiltration . Chin Tradit Herb Drugs(中草药), 2011, 42 (8):1523-1527. WANG Y, GAO X M, ZHANG B L. Study on Guanxin salvia drop pill to pituitary induced acute myocardium ischemia . Chin J Integr Tradit West Med Intensive Crit Care(中国中西医结合急救杂志), 2003, 10 (1):6-8. TORCHILIN V P. Recent advances with liposomes as pharmaceutical carriers . Nat Rev Drug Discov, 2005, 4 (2):145-160. LEE C M, LEE H C, LEE K Y. O-Palmitoylcurdlan sulfate (OPCurS)-coated liposomes for oral drug delivery . J Biosci Bioeng, 2005, 100 (3):255-259. RAI S, PALIWAL R, GUPTA P N, et al. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science:One step up in nanotechnology . Curr Nanosci, 2008, 4 (1):30-44. GOVENDER T, RILEY T, EHTEZAZI T, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm, 2000, 199 (1):95-110. ZHAI Y S, DU S Y, XU B, et al. O/W Partition coefficient of PNS and absorption kinetics of it in rat intestine. China J Chin Mater Med (中国中药杂志), 2010, 35 (8):984-988. WANG J Q, ZHANG Q. Nanoparticulate Drug Delivery Systems (纳米药物输送系统) . Beijing:Peking University Medical Press, 2010:59. WEI X H. Researches on the applications of PEGylated chitosan in microparticular drug delivery system (PEG化壳聚糖在微粒给药系统中应用的研究) . Zhejiang:Doctorate Dissertation of Zhejiang University, 2004. ALLEN T M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery . Trends Pharmacol Sci, 1994, 15 (7):215-220.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
